NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
16
MEDIF Quote, Financials, Valuation and Earnings
Last price:
$0.04
Seasonality move
:
14.13%
Day range:
$0.04 - $0.04
52-week range:
$0.04 - $0.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.60x
P/B ratio:
0.53x
Volume:
291.5K
Avg. volume:
171.4K
1-year change:
-10.21%
Market cap:
$17.7M
Revenue:
$24.5M
EPS (TTM):
-$0.03
Analysts' Opinion
-
Consensus RatingMediPharm Labs has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, MediPharm Labs has an estimated downside of -- from its current price of $0.04.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $0.04.
Fair Value
-
According to the consensus of 0 analysts, MediPharm Labs has -- downside to fair value with a price target of -- per share.
MEDIF vs. S&P 500
-
Over the past 5 trading days, MediPharm Labs has underperformed the S&P 500 by -2.28% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
MediPharm Labs does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MediPharm Labs has grown year-over-year revenues for 7 quarters straight. In the most recent quarter MediPharm Labs reported revenues of $7.2M.
Earnings Growth
-
MediPharm Labs has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MediPharm Labs reported earnings per share of -$0.01.
Enterprise value:
8.5M
EV / Invested capital:
0.25x
Price / LTM sales:
0.60x
EV / EBIT:
--
EV / Revenue:
0.29x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-4.71x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$8.4M
Return On Assets:
-18.91%
Net Income Margin (TTM):
-30.13%
Return On Equity:
-23.29%
Return On Invested Capital:
-22.42%
Operating Margin:
-27.64%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $17.4M | $21.9M | $28.7M | $6.3M | $7.2M | |
| Gross Profit | -$5.6M | $2.9M | $8.4M | $1.8M | $2.3M | |
| Operating Income | -$32.1M | -$14.4M | -$8.4M | -$3.2M | -$2M | |
| EBITDA | -$32.5M | -$9.8M | -$6.3M | -$2.7M | -$1.5M | |
| Diluted EPS | -$0.13 | -$0.04 | -$0.03 | -$0.01 | -$0.01 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $75.5M | $66.5M | $38.2M | $30.7M | $25.6M | |
| Total Assets | $112.2M | $92.7M | $52.1M | $50M | $41.3M | |
| Current Liabilities | $11M | $12.1M | $7.8M | $9.4M | $8M | |
| Total Liabilities | $34.3M | $12.2M | $7.9M | $9.4M | $8M | |
| Total Equity | $77.9M | $80.4M | $44.2M | $40.6M | $33.3M | |
| Total Debt | $22.9M | $1.5M | $759K | $1.8M | $422.6K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15.4M | -$10.5M | -$1.6M | -$2.4M | -$491.9K | |
| Cash From Investing | -$196.5K | $6.3M | $3.5M | $1.2M | -$23.1K | |
| Cash From Financing | $1M | -$398K | -$1.4M | -$222.5K | -$1.6M | |
| Free Cash Flow | -$16M | -$11M | -$1.8M | -$2.6M | -$516.2K | |
MEDIF
Sector
Market Cap
$17.7M
$43.9M
Price % of 52-Week High
57.7%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-10.21%
-29.11%
Beta (5-Year)
0.974
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.05
200-day SMA
Sell
Level
$0.05
Bollinger Bands (100)
Sell
Level
0.05 - 0.05
Chaikin Money Flow
Sell
Level
-27.8M
20-day SMA
Sell
Level
$0.05
Relative Strength Index (RSI14)
Sell
Level
38.21
ADX Line
Sell
Level
13.78
Williams %R
Neutral
Level
-74.1935
50-day SMA
Sell
Level
$0.05
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Sell
Level
-44.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.1167)
Buy
CA Score
(Annual)
Level (0.4049)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.347)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.
Stock Forecast FAQ
In the current month, MEDIF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MEDIF average analyst price target in the past 3 months is --.
-
Where Will MediPharm Labs Stock Be In 1 Year?
According to analysts, the consensus estimate is that MediPharm Labs share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About MediPharm Labs?
Analysts are divided on their view about MediPharm Labs share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MediPharm Labs is a Sell and believe this share price will rise from its current level to --.
-
What Is MediPharm Labs's Price Target?
The price target for MediPharm Labs over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MEDIF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MediPharm Labs is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MEDIF?
You can purchase shares of MediPharm Labs via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MediPharm Labs shares.
-
What Is The MediPharm Labs Share Price Today?
MediPharm Labs was last trading at $0.04 per share. This represents the most recent stock quote for MediPharm Labs. Yesterday, MediPharm Labs closed at $0.04 per share.
-
How To Buy MediPharm Labs Stock Online?
In order to purchase MediPharm Labs stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 2.13% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 2.88% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 6.16% over the past day.
